Results 231 to 240 of about 2,636,320 (328)
Platelet-derived growth factor (PDGF) and its impact in fibroid pathogenesis: A narrative review. [PDF]
Obeagu EI.
europepmc +1 more source
There is no suitable radioligand for positron emission tomography imaging of CB2R overexpression for routine clinical usage. Herein, the synthesis, characterization, binding affinity, and docking studies of carborane‐based halo‐substituted naphthyridinone derivatives as CB2R ligands are presented.
Lea Ueberham+4 more
wiley +1 more source
Impact of Endocrine Therapy on Osteoporosis Risk in Women with Breast Cancer Across Different Hormonal Stages: A Review. [PDF]
Gomes B, Vale N.
europepmc +1 more source
Highly Sensitive, Low‐Cost Deep‐UV Resonant Raman Microspectroscopy Systems
Low‐cost deep UV resonant Raman microscope for chemical sensing and imaging has been developed and its performance has been experimentally validated for several potential applications. Multimodal imaging capabilities of a new instrument have been demonstrated as well.
Joseph Harrington+5 more
wiley +1 more source
Single-cell RNA sequencing reveals the potential role of estrogen in tuberous sclerosis complex related renal angiomyolipoma. [PDF]
Liu Y+10 more
europepmc +1 more source
Estrogen receptors and the metabolic network.
R. Barros, J. Gustafsson
semanticscholar +1 more source
Abstract Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne ...
Andrea Francesco Daniele Di Stefano+8 more
wiley +1 more source
Mini review: Bidirectional Regulation of Circadian Rhythm by Suprachiasmatic Nucleus and Nuclear Receptors in Female Mammals. [PDF]
Shanmugam DAS+11 more
europepmc +1 more source
Deciphering the transcriptomic landscape of early HR+/HER2− breast cancer in very young women
Cancer Communications, EarlyView.
Iris Garrido‐Cano+15 more
wiley +1 more source
Abstract Imlunestrant (LY3484356) is a next‐generation orally bioavailable selective estrogen receptor degrader being investigated for the treatment of estrogen receptor–positive advanced breast and endometrial cancers. This Phase 1, open‐label, 2‐part study evaluated the disposition and absolute bioavailability of [14C]‐imlunestrant in 16 US‐based ...
Amita Datta‐Mannan+6 more
wiley +1 more source